Structure
LY518674, inhibitor
LY518674
Purity
98.00%
Synonyms
LY518674; LY-674; inhibitor
Purity/Purification
98.00%
Form/Format
Solid. Powder
Solubility
DMSO: 250mg/mL (610.53mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C23H27N3O4
SMILES
CC(C)(OC1=CC=C(CCCC2=NC(N(CC3=CC=C(C)C=C3)N2)=O)C=C1)C(O)=O
CAS Number
425671-29-0
Target & IC50
human PPARalpha: ic50 42nM (EC50)
In Vitro
LY518674 decreases triglycerides and increased HDL-C in vivo[2]. LY518674 significantly enhances apolipoprotein A-I (apoA-I) turnover without a major impact on steady-state levels of apoA-I or high-density lipoprotein-cholesterol (HDL-C) [3].
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
-80 degree C for 2 years in solvent
Structure
Structure
Related Product Information for LY518674, inhibitor
LY518674 decreases triglycerides in and increased HDL-C and is used for the treatment,of atherosclerosis. LY518674 is an effective and selective PPARalpha antagonist (EC50: 42nM for human PPARalpha).
Product Categories/Family for LY518674, inhibitor
References
Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARalpha antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72.
Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARalpha antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72.
Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73.
Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73.
Khera AV, et al. Potent peroxisome proliferator-activated receptor-alpha agonist treatment,increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36(43):3020-2.
Khera AV, et al. Potent peroxisome proliferator-activated receptor-alpha agonist treatment,increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36(43):3020-2.
Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARalpha antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72.
Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73.
Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73.
Khera AV, et al. Potent peroxisome proliferator-activated receptor-alpha agonist treatment,increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36(43):3020-2.
Khera AV, et al. Potent peroxisome proliferator-activated receptor-alpha agonist treatment,increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36(43):3020-2.
Similar Products
Product Notes
The LY518674 (Catalog #AAA5755146) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "LY518674, Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
